S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EVAX

Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis

$3.20
+0.20 (+6.67%)
(As of 03/28/2024 ET)
Today's Range
$3.00
$3.20
50-Day Range
$2.90
$10.65
52-Week Range
$2.82
$18.50
Volume
17,189 shs
Average Volume
688,900 shs
Market Capitalization
$12.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Evaxion Biotech A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,212.5% Upside
$42.00 Price Target
Short Interest
Healthy
1.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Evaxion Biotech A/S in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.55) to ($1.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

503rd out of 938 stocks

Biological Products, Except Diagnostic Industry

81st out of 149 stocks

EVAX stock logo

About Evaxion Biotech A/S Stock (NASDAQ:EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

EVAX Stock Price History

EVAX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Evaxion Biotech AS (EVAX)
Evaxion Announces Closing of $15 Million Public Offering
ADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%
See More Headlines
Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/19/2023
Today
3/28/2024
Next Earnings (Estimated)
5/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EVAX
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.00
High Stock Price Target
$70.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+1,212.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-23,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.48 per share

Miscellaneous

Free Float
2,366,000
Market Cap
$12.97 million
Optionable
Optionable
Beta
-0.01
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Christian Kanstrup M.Sc. (Age 52)
    Chief Executive Officer
    Comp: $454k
  • Mr. Andreas Holm Mattsson (Age 48)
    Co-Founder and Chief AI & Culture Officer
    Comp: $247k
  • Dr. Niels Iversen Moller M.D. (Age 45)
    Co-Founder, VP of Business & Director
    Comp: $120k
  • Mr. Jesper Nyegaard Nissen M.Sc. (Age 53)
    CFO & COO
    Comp: $346.97k
  • Dr. Birgitte Rono Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $336k
  • Dr. Jürgen Langhärig EMBA
    Ph.D., Head of Business Development & Member of Advisory Board

EVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EVAX shares.
View EVAX analyst ratings
or view top-rated stocks.

What is Evaxion Biotech A/S's stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for Evaxion Biotech A/S's stock. Their EVAX share price targets range from $14.00 to $70.00. On average, they anticipate the company's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 1,212.5% from the stock's current price.
View analysts price targets for EVAX
or view top-rated stocks among Wall Street analysts.

How have EVAX shares performed in 2024?

Evaxion Biotech A/S's stock was trading at $6.8570 on January 1st, 2024. Since then, EVAX stock has decreased by 53.3% and is now trading at $3.20.
View the best growth stocks for 2024 here
.

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 43,000 shares, an increase of 56.4% from the February 29th total of 27,500 shares. Based on an average daily volume of 646,300 shares, the days-to-cover ratio is presently 0.1 days.
View Evaxion Biotech A/S's Short Interest
.

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024.
View our EVAX earnings forecast
.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) released its quarterly earnings results on Tuesday, December, 19th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.90) by $0.20.

When did Evaxion Biotech A/S's stock split?

Shares of Evaxion Biotech A/S reverse split on Monday, January 22nd 2024. The 1-10 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Evaxion Biotech A/S IPO?

Evaxion Biotech A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are Evaxion Biotech A/S's major shareholders?

Evaxion Biotech A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include LM Advisors LLC (8.90%), Beacon Capital Management LLC (0.17%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVAX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners